Novartis plans to spin off generics division Sandoz
Sandoz is the last remaining name of the pre-Novartis era. Novartis, founded in 1996, is the product of various mergers over its more than 100 year history.
Keystone / Georgios Kefalas
Swiss pharma firm Novartis has said it plans to spin off its generics and biosimilars division Sandoz into a separate entity to allow both companies to pursue their own growth strategies.
This content was published on
3 minutes
Keystone-SDA/jdp
Español
es
Novartis proyecta escindir la división de genéricos Sandoz
The decision was in the best interest of shareholders, said Novartis CEO Vas Narasimhan in a media call on Thursday.
Late last year the Basel-based company said it was conducting a strategic review of Sandoz and considering all options, including spinning off the company into a separate entity. Many analysts predicted an IPO was the most likely scenario. Sandoz reaped $9.8 billion (CHF9.4 billion) in worldwide sales last year, but it has seen revenue decline in its key market in the US.
More
More
What’s behind the Novartis job cuts?
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure – it’s a turning point for Novartis.
The split will create the largest European generics company and create a “more focused Novartis”, according to a press releaseExternal link.
In April Novartis announced a major restructuring to focus on “innovative medicines” – combining its pharmaceutical and oncology divisions. This led the company to shed 7% of its workforce globally. In Switzerland, it said it would cut 10% of its workforce, which means 1,400 jobs will disappear, many of which are in management positions.
More
More
Swiss pharma reckons with its past, present and future
This content was published on
This is the story of how making drugs helped turn a small, mountainous country into an industry titan, and what the pandemic means for its future.
Since Narasimhan took over the CEO post in 2018, Novartis has been shedding parts of its business. It sold its consumer healthcare unit to GSK and spun off its eyecare division Alcon into a separate entity in 2019.
Future of Sandoz
Sandoz will list on the SIX Swiss Exchange and will remain a Swiss company. However, the specific location of the company’s headquarters has not been determined. Current Sandoz CEO Richard Saynor will continue to lead the company. The board of directors of the future independent company will be formed shortly, Narasimhan added.
No further layoffs are expected at Sandoz as a result of the spin-off. On the contrary, said Narasimhan, “we are currently building up the necessary functions for an independent company”. Further details on the timeline for the spin-off have not been provided.
Novartis is one of the largest pharmaceutical companies in the world. Prior to the recent restructuring, it employed more than 100,000 people worldwide.
More
More
Can Novartis’s sustainability-linked bond make good on its promises?
This content was published on
Novartis’s sustainability-linked bond was a world first for the pharmaceutical industry. But will it improve access to medicine?
As a key maker of antibiotics and off-patent medicines, Sandoz has played a key role in Novartis’ approach to expanding access to medicines in low- and middle-income countries. In an emailed response to SWI, a Novartis company spokesperson said that Novartis remains committed to its global health programs and targets. “The plan is for Sandoz to continue to supply key products to Novartis for distribution in certain key Global Health markets, primarily in Sub-Saharan Africa,” wrote the spokesperson.
Popular Stories
More
Banking & Fintech
Luxury heir claims his CHF11 billion Hermès fortune has vanished
What can be done to protect biodiversity in your country?
Swiss voters are set to decide on a people’s initiative calling for better protection of ecosystems in the country. Have your say on the September 22 vote.
Swiss investigate four people linked to Russian oligarch
This content was published on
The Office of the Attorney General of Switzerland is investigating four individuals linked to Russian oligarch Suleyman Kerimov.
Swiss government scrambles to deal with egg shortage
This content was published on
From September 1, more eggs intended for consumption may be imported into Switzerland. In allowing this, the government wants to secure the supply of eggs for consumers.
This content was published on
Agricultural research sees new development opportunities for Swiss sparkling wines in the face of declining wine consumption. In a survey, half of consumers expressed a willingness to pay more for local products than for foreign ones.
Locarno spotlights filmmakers from South America and Caribbean
This content was published on
The Open Doors section of the Locarno Film Festival has named the winners for 2024. The spotlight is on the South American and Caribbean regions.
Storm paralyses trains to popular Swiss tourist resort
This content was published on
The railway line between Zweilütschinen and Grindelwald in central Switzerland is expected to remain closed until Friday following heavy rains.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis job cuts to heavily impact management roles
This content was published on
Of the 1,400 job cuts announced by the pharma giant in Switzerland, up to half of them will involve executive-level staff.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.